[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGQmPhTGK-P4NDNcnANDnR6iG1D_RGRRAet98oTGCUXc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":55,"rows":62},"University of Ulm",[4],143,false,29,15,94525,7,91,[14,17,20,22,24,27,29,32],{"name":15,"count":16},"Acute Myeloid Leukemia",12,{"name":18,"count":19},"Acute Myeloid Leukemia (AML)",6,{"name":21,"count":19},"Amyotrophic Lateral Sclerosis",{"name":23,"count":19},"Coronary Artery Disease",{"name":25,"count":26},"Sepsis",4,{"name":28,"count":26},"Critically Ill",{"name":30,"count":31},"Obesity",3,{"name":33,"count":31},"SIRS",[35,40,45,50],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05191381","Immune Modulation by Exosomes in COVID-19","2025-07-31","Application of exosomes in a whole blood assay",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03897127","Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics","2027-06","Cytarabine",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04881682","Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","2027-09-01","Immunoglobulins",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT04628026","Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","2029-03","Venetoclax",[56,57,58,59,60,61],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[63,188,223,257,289,307,329,354,381,409,436,454,480,506,524,549,567,591,609,650,680,706,732,754,776,801,819,844,862,889,916,934,952,970,988,1016,1041,1065,1092,1118,1136,1154,1179,1204,1228,1254,1272,1305,1323,1341,1359,1377,1395,1413,1431,1449,1467,1491,1516,1546,1564,1593,1611,1629,1655,1673,1691,1709,1727,1751,1785,1810,1832,1859,1886,1911,1938,1956],{"intervention":44,"totalTrials":64,"cells":65},10,{"EARLY_PHASE1":66,"PHASE1":69,"PHASE2":71,"PHASE3":134,"PHASE4":184,"NA":186},{"trials":67,"activeCount":68},[],0,{"trials":70,"activeCount":68},[],{"trials":72,"activeCount":68},[73,85,98,110,124],{"nctId":74,"briefTitle":75,"status":76,"phases":77,"primaryCompletion":78,"completion":78,"start":79,"enrollment":80,"conditions":81,"interventions":82},"NCT00850382","Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)","COMPLETED",[57,58],"2015-11","2009-06",89,[18],[83,84,44],"Dasatinib","daunorubicin",{"nctId":86,"briefTitle":87,"status":88,"phases":89,"primaryCompletion":90,"completion":90,"start":91,"enrollment":19,"conditions":92,"interventions":94},"NCT02198482","Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)","TERMINATED",[58],"2016-11","2016-02",[18,93],"High-risk Myelodysplastic Syndrome (MDS)",[95,44,96,97],"Volasertib","Daunorubicin","Mitoxantrone",{"nctId":99,"briefTitle":100,"status":76,"phases":101,"primaryCompletion":102,"completion":79,"start":103,"enrollment":104,"conditions":105,"interventions":107},"NCT00143975","Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)",[58],"2007-07","2004-06",95,[106],"Leukemia, Myeloid, Acute",[44,97,108,109],"Gemtuzumab Ozogamicin","All-trans-Retinoid Acid",{"nctId":111,"briefTitle":112,"status":76,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":119},"NCT01180322","Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine",[58],"2012-06","2016-10-02","2010-11",277,[18],[44,120,121,122,123],"Idarubicin","Etoposide","Azacitidine","Lenograstim",{"nctId":125,"briefTitle":126,"status":76,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":132},"NCT01477606","Protocol in Acute Myeloid Leukemia With FLT3-ITD",[58],"2020-02-26","2012-05",451,[15],[133,44,96],"Midostaurin",{"trials":135,"activeCount":183,"soonestReadout":43},[136,148,156,165,174],{"nctId":137,"briefTitle":138,"status":76,"phases":139,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":145},"NCT00151242","Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia",[58,59],"2011-08","2013-08","2004-07",920,[15],[44,120,121,146,147],"All-trans retinoic acid","Pegfilgrastim",{"nctId":41,"briefTitle":42,"status":149,"phases":150,"primaryCompletion":43,"completion":43,"start":151,"enrollment":152,"conditions":153,"interventions":154},"ACTIVE_NOT_RECRUITING",[59],"2019-09-04",882,[15],[44,96,155],"CPX-351",{"nctId":157,"briefTitle":158,"status":76,"phases":159,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":164},"NCT02013648","Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)",[59],"2024-02","2014-07",204,[18],[83,44,96,120],{"nctId":166,"briefTitle":167,"status":76,"phases":168,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":173},"NCT01237808","Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation",[59],"2018-07-13","2011-03",144,[18],[44,121,146],{"nctId":175,"briefTitle":176,"status":76,"phases":177,"primaryCompletion":79,"completion":178,"start":103,"enrollment":179,"conditions":180,"interventions":181},"NCT00151255","All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia",[59],"2011-01",500,[15],[44,120,146,97,182],"Etoposid",1,{"trials":185,"activeCount":68},[],{"trials":187,"activeCount":68},[],{"intervention":96,"totalTrials":189,"cells":190},5,{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":209,"PHASE4":219,"NA":221},{"trials":192,"activeCount":68},[],{"trials":194,"activeCount":68},[],{"trials":196,"activeCount":68},[197,201,205],{"nctId":74,"briefTitle":75,"status":76,"phases":198,"primaryCompletion":78,"completion":78,"start":79,"enrollment":80,"conditions":199,"interventions":200},[57,58],[18],[83,84,44],{"nctId":86,"briefTitle":87,"status":88,"phases":202,"primaryCompletion":90,"completion":90,"start":91,"enrollment":19,"conditions":203,"interventions":204},[58],[18,93],[95,44,96,97],{"nctId":125,"briefTitle":126,"status":76,"phases":206,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":207,"interventions":208},[58],[15],[133,44,96],{"trials":210,"activeCount":183,"soonestReadout":43},[211,215],{"nctId":41,"briefTitle":42,"status":149,"phases":212,"primaryCompletion":43,"completion":43,"start":151,"enrollment":152,"conditions":213,"interventions":214},[59],[15],[44,96,155],{"nctId":157,"briefTitle":158,"status":76,"phases":216,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":217,"interventions":218},[59],[18],[83,44,96,120],{"trials":220,"activeCount":68},[],{"trials":222,"activeCount":68},[],{"intervention":224,"totalTrials":225,"cells":226},"standard chemotherapy",2,{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":253,"NA":255},{"trials":228,"activeCount":68},[],{"trials":230,"activeCount":68},[],{"trials":232,"activeCount":68},[],{"trials":234,"activeCount":183,"soonestReadout":53},[235,244],{"nctId":236,"briefTitle":237,"status":76,"phases":238,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT00893399","Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation",[59],"2021-09-01","2010-05-12",600,[15],[108,224],{"nctId":51,"briefTitle":52,"status":245,"phases":246,"primaryCompletion":53,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":251},"RECRUITING",[59],"2032-02","2022-09-13",650,[15],[54,252],"Standard chemotherapy",{"trials":254,"activeCount":68},[],{"trials":256,"activeCount":68},[],{"intervention":258,"totalTrials":225,"cells":259},"venetoclax",{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":279,"PHASE4":285,"NA":287},{"trials":261,"activeCount":68},[],{"trials":263,"activeCount":68},[],{"trials":265,"activeCount":68},[266],{"nctId":267,"briefTitle":268,"status":76,"phases":269,"primaryCompletion":270,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT02758665","Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL",[58],"2022-01","2022-03","2016-09",41,[275],"Leukemia, Lymphocytic, Chronic",[277,278,258],"ibrutinib","obinutuzumab",{"trials":280,"activeCount":183,"soonestReadout":53},[281],{"nctId":51,"briefTitle":52,"status":245,"phases":282,"primaryCompletion":53,"completion":247,"start":248,"enrollment":249,"conditions":283,"interventions":284},[59],[15],[54,252],{"trials":286,"activeCount":68},[],{"trials":288,"activeCount":68},[],{"intervention":155,"totalTrials":183,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":303,"NA":305},{"trials":292,"activeCount":68},[],{"trials":294,"activeCount":68},[],{"trials":296,"activeCount":68},[],{"trials":298,"activeCount":183,"soonestReadout":43},[299],{"nctId":41,"briefTitle":42,"status":149,"phases":300,"primaryCompletion":43,"completion":43,"start":151,"enrollment":152,"conditions":301,"interventions":302},[59],[15],[44,96,155],{"trials":304,"activeCount":68},[],{"trials":306,"activeCount":68},[],{"intervention":49,"totalTrials":183,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":323,"PHASE4":325,"NA":327},{"trials":310,"activeCount":68},[],{"trials":312,"activeCount":68},[],{"trials":314,"activeCount":183,"soonestReadout":48},[315],{"nctId":46,"briefTitle":47,"status":245,"phases":316,"primaryCompletion":48,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":322},[58],"2028-03-01","2023-05-01",20,[321],"CIDP",[49],{"trials":324,"activeCount":68},[],{"trials":326,"activeCount":68},[],{"trials":328,"activeCount":68},[],{"intervention":39,"totalTrials":183,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":332,"activeCount":68},[],{"trials":334,"activeCount":68},[],{"trials":336,"activeCount":68},[],{"trials":338,"activeCount":68},[],{"trials":340,"activeCount":68},[],{"trials":342,"activeCount":183,"soonestReadout":38},[343],{"nctId":36,"briefTitle":37,"status":245,"phases":344,"primaryCompletion":38,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":353},[],"2026-12-31","2021-12-22",40,[349,350,351,352],"COVID-19","Critical Illness","Hypercytokinemia","Lung Fibrosis",[39],{"intervention":355,"totalTrials":183,"cells":356},"Ertapenem",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":379},{"trials":358,"activeCount":68},[],{"trials":360,"activeCount":68},[],{"trials":362,"activeCount":68},[],{"trials":364,"activeCount":68},[],{"trials":366,"activeCount":68},[367],{"nctId":368,"briefTitle":369,"status":76,"phases":370,"primaryCompletion":371,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":378},"NCT00535652","Concentration of Ertapenem in Colorectal Tissue",[60],"2009-12","2007-09",23,[375,376,377],"Diverticulosis, Colonic","Rectal Neoplasms","Colonic Neoplasms",[355],{"trials":380,"activeCount":68},[],{"intervention":382,"totalTrials":183,"cells":383},"peginterferon alfa-2a and ribavirin",{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":407},{"trials":385,"activeCount":68},[],{"trials":387,"activeCount":68},[],{"trials":389,"activeCount":68},[],{"trials":391,"activeCount":68},[],{"trials":393,"activeCount":68},[394],{"nctId":395,"briefTitle":396,"status":76,"phases":397,"primaryCompletion":398,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":406},"NCT00948220","Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C",[60],"2007-01","2008-03","2003-07",26,[403,404,405],"Hepatitis C, Chronic","Liver Diseases","Virus Diseases",[382],{"trials":408,"activeCount":68},[],{"intervention":410,"totalTrials":183,"cells":411},"Dobutamine",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":434},{"trials":413,"activeCount":68},[],{"trials":415,"activeCount":68},[],{"trials":417,"activeCount":68},[],{"trials":419,"activeCount":68},[],{"trials":421,"activeCount":68},[422],{"nctId":423,"briefTitle":424,"status":425,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":319,"conditions":430,"interventions":432},"NCT01427686","Dopamine Versus Dobutamine for Treatment of Arterial Hypotension in Term and Preterm Neonates","UNKNOWN",[60],"2015-02","2016-12","2011-06",[431],"Arterial Hypotension",[410,433],"Dopamine",{"trials":435,"activeCount":68},[],{"intervention":433,"totalTrials":183,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":446,"NA":452},{"trials":439,"activeCount":68},[],{"trials":441,"activeCount":68},[],{"trials":443,"activeCount":68},[],{"trials":445,"activeCount":68},[],{"trials":447,"activeCount":68},[448],{"nctId":423,"briefTitle":424,"status":425,"phases":449,"primaryCompletion":427,"completion":428,"start":429,"enrollment":319,"conditions":450,"interventions":451},[60],[431],[410,433],{"trials":453,"activeCount":68},[],{"intervention":455,"totalTrials":183,"cells":456},"Atropine, Fentanyl, Mivacurium",{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":463,"PHASE4":465,"NA":478},{"trials":458,"activeCount":68},[],{"trials":460,"activeCount":68},[],{"trials":462,"activeCount":68},[],{"trials":464,"activeCount":68},[],{"trials":466,"activeCount":68},[467],{"nctId":468,"briefTitle":469,"status":76,"phases":470,"primaryCompletion":471,"completion":471,"start":429,"enrollment":472,"conditions":473,"interventions":477},"NCT01427985","Influence of Premedication Protocols for Neonatal Endotracheal Intubation on Cerebral Oxygenation",[60],"2012-07",24,[474,475,476],"Newborn","Preterm","Intubation",[455,455],{"trials":479,"activeCount":68},[],{"intervention":481,"totalTrials":183,"cells":482},"Dabigatranetexilate",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":504},{"trials":484,"activeCount":68},[],{"trials":486,"activeCount":68},[],{"trials":488,"activeCount":68},[],{"trials":490,"activeCount":68},[],{"trials":492,"activeCount":68},[493],{"nctId":494,"briefTitle":495,"status":425,"phases":496,"primaryCompletion":497,"start":498,"enrollment":347,"conditions":499,"interventions":502},"NCT02591225","Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon",[60],"2017-12","2015-10",[500,501],"Atrial Fibrillation","Left Atrial Thrombosis",[481,503],"Phenprocoumon",{"trials":505,"activeCount":68},[],{"intervention":503,"totalTrials":183,"cells":507},{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":516,"NA":522},{"trials":509,"activeCount":68},[],{"trials":511,"activeCount":68},[],{"trials":513,"activeCount":68},[],{"trials":515,"activeCount":68},[],{"trials":517,"activeCount":68},[518],{"nctId":494,"briefTitle":495,"status":425,"phases":519,"primaryCompletion":497,"start":498,"enrollment":347,"conditions":520,"interventions":521},[60],[500,501],[481,503],{"trials":523,"activeCount":68},[],{"intervention":525,"totalTrials":183,"cells":526},"Moxifloxacin",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":535,"NA":547},{"trials":528,"activeCount":68},[],{"trials":530,"activeCount":68},[],{"trials":532,"activeCount":68},[],{"trials":534,"activeCount":68},[],{"trials":536,"activeCount":68},[537],{"nctId":538,"briefTitle":539,"status":88,"phases":540,"primaryCompletion":178,"completion":178,"start":541,"enrollment":542,"conditions":543,"interventions":545},"NCT00887276","Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin\u002FAmoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia",[60],"2008-11",290,[544],"Community Acquired Pneumonia",[525,546],"Ampicillin;Amoxicillin",{"trials":548,"activeCount":68},[],{"intervention":546,"totalTrials":183,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":559,"NA":565},{"trials":552,"activeCount":68},[],{"trials":554,"activeCount":68},[],{"trials":556,"activeCount":68},[],{"trials":558,"activeCount":68},[],{"trials":560,"activeCount":68},[561],{"nctId":538,"briefTitle":539,"status":88,"phases":562,"primaryCompletion":178,"completion":178,"start":541,"enrollment":542,"conditions":563,"interventions":564},[60],[544],[525,546],{"trials":566,"activeCount":68},[],{"intervention":568,"totalTrials":183,"cells":569},"Lamivudine",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":578,"NA":589},{"trials":571,"activeCount":68},[],{"trials":573,"activeCount":68},[],{"trials":575,"activeCount":68},[],{"trials":577,"activeCount":68},[],{"trials":579,"activeCount":68},[580],{"nctId":581,"briefTitle":582,"status":583,"phases":584,"enrollment":347,"conditions":585,"interventions":587},"NCT00710216","Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B","WITHDRAWN",[60],[586],"Hepatitis B, Chronic",[568,588],"Telbivudine",{"trials":590,"activeCount":68},[],{"intervention":588,"totalTrials":183,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":601,"NA":607},{"trials":594,"activeCount":68},[],{"trials":596,"activeCount":68},[],{"trials":598,"activeCount":68},[],{"trials":600,"activeCount":68},[],{"trials":602,"activeCount":68},[603],{"nctId":581,"briefTitle":582,"status":583,"phases":604,"enrollment":347,"conditions":605,"interventions":606},[60],[586],[568,588],{"trials":608,"activeCount":68},[],{"intervention":120,"totalTrials":189,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":621,"PHASE4":646,"NA":648},{"trials":612,"activeCount":68},[],{"trials":614,"activeCount":68},[],{"trials":616,"activeCount":68},[617],{"nctId":111,"briefTitle":112,"status":76,"phases":618,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":619,"interventions":620},[58],[18],[44,120,121,122,123],{"trials":622,"activeCount":68},[623,627,631,642],{"nctId":137,"briefTitle":138,"status":76,"phases":624,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":625,"interventions":626},[58,59],[15],[44,120,121,146,147],{"nctId":157,"briefTitle":158,"status":76,"phases":628,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":629,"interventions":630},[59],[18],[83,44,96,120],{"nctId":632,"briefTitle":633,"status":76,"phases":634,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":639},"NCT00146120","Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result",[59],"2005-05","1998-05",400,[15],[120,640,121,641],"Cytosin-Arabinosid","All-trans Retinoid acid",{"nctId":175,"briefTitle":176,"status":76,"phases":643,"primaryCompletion":79,"completion":178,"start":103,"enrollment":179,"conditions":644,"interventions":645},[59],[15],[44,120,146,97,182],{"trials":647,"activeCount":68},[],{"trials":649,"activeCount":68},[],{"intervention":121,"totalTrials":26,"cells":651},{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":662,"PHASE4":676,"NA":678},{"trials":653,"activeCount":68},[],{"trials":655,"activeCount":68},[],{"trials":657,"activeCount":68},[658],{"nctId":111,"briefTitle":112,"status":76,"phases":659,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":660,"interventions":661},[58],[18],[44,120,121,122,123],{"trials":663,"activeCount":68},[664,668,672],{"nctId":137,"briefTitle":138,"status":76,"phases":665,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":666,"interventions":667},[58,59],[15],[44,120,121,146,147],{"nctId":632,"briefTitle":633,"status":76,"phases":669,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":670,"interventions":671},[59],[15],[120,640,121,641],{"nctId":166,"briefTitle":167,"status":76,"phases":673,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":674,"interventions":675},[59],[18],[44,121,146],{"trials":677,"activeCount":68},[],{"trials":679,"activeCount":68},[],{"intervention":146,"totalTrials":31,"cells":681},{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":702,"NA":704},{"trials":683,"activeCount":68},[],{"trials":685,"activeCount":68},[],{"trials":687,"activeCount":68},[],{"trials":689,"activeCount":68},[690,694,698],{"nctId":137,"briefTitle":138,"status":76,"phases":691,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":692,"interventions":693},[58,59],[15],[44,120,121,146,147],{"nctId":166,"briefTitle":167,"status":76,"phases":695,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":696,"interventions":697},[59],[18],[44,121,146],{"nctId":175,"briefTitle":176,"status":76,"phases":699,"primaryCompletion":79,"completion":178,"start":103,"enrollment":179,"conditions":700,"interventions":701},[59],[15],[44,120,146,97,182],{"trials":703,"activeCount":68},[],{"trials":705,"activeCount":68},[],{"intervention":97,"totalTrials":31,"cells":707},{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":722,"PHASE4":728,"NA":730},{"trials":709,"activeCount":68},[],{"trials":711,"activeCount":68},[],{"trials":713,"activeCount":68},[714,718],{"nctId":86,"briefTitle":87,"status":88,"phases":715,"primaryCompletion":90,"completion":90,"start":91,"enrollment":19,"conditions":716,"interventions":717},[58],[18,93],[95,44,96,97],{"nctId":99,"briefTitle":100,"status":76,"phases":719,"primaryCompletion":102,"completion":79,"start":103,"enrollment":104,"conditions":720,"interventions":721},[58],[106],[44,97,108,109],{"trials":723,"activeCount":68},[724],{"nctId":175,"briefTitle":176,"status":76,"phases":725,"primaryCompletion":79,"completion":178,"start":103,"enrollment":179,"conditions":726,"interventions":727},[59],[15],[44,120,146,97,182],{"trials":729,"activeCount":68},[],{"trials":731,"activeCount":68},[],{"intervention":83,"totalTrials":225,"cells":733},{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":744,"PHASE4":750,"NA":752},{"trials":735,"activeCount":68},[],{"trials":737,"activeCount":68},[],{"trials":739,"activeCount":68},[740],{"nctId":74,"briefTitle":75,"status":76,"phases":741,"primaryCompletion":78,"completion":78,"start":79,"enrollment":80,"conditions":742,"interventions":743},[57,58],[18],[83,84,44],{"trials":745,"activeCount":68},[746],{"nctId":157,"briefTitle":158,"status":76,"phases":747,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":748,"interventions":749},[59],[18],[83,44,96,120],{"trials":751,"activeCount":68},[],{"trials":753,"activeCount":68},[],{"intervention":108,"totalTrials":225,"cells":755},{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":766,"PHASE4":772,"NA":774},{"trials":757,"activeCount":68},[],{"trials":759,"activeCount":68},[],{"trials":761,"activeCount":68},[762],{"nctId":99,"briefTitle":100,"status":76,"phases":763,"primaryCompletion":102,"completion":79,"start":103,"enrollment":104,"conditions":764,"interventions":765},[58],[106],[44,97,108,109],{"trials":767,"activeCount":68},[768],{"nctId":236,"briefTitle":237,"status":76,"phases":769,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":770,"interventions":771},[59],[15],[108,224],{"trials":773,"activeCount":68},[],{"trials":775,"activeCount":68},[],{"intervention":777,"totalTrials":183,"cells":778},"chemotherapy",{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":785,"PHASE4":797,"NA":799},{"trials":780,"activeCount":68},[],{"trials":782,"activeCount":68},[],{"trials":784,"activeCount":68},[],{"trials":786,"activeCount":68},[787],{"nctId":788,"briefTitle":789,"status":88,"phases":790,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":794,"interventions":795},"NCT02298166","Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations",[59],"2020-03-09","2016-11-17",9,[15],[777,796],"Crenolanib",{"trials":798,"activeCount":68},[],{"trials":800,"activeCount":68},[],{"intervention":796,"totalTrials":183,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":809,"PHASE4":815,"NA":817},{"trials":804,"activeCount":68},[],{"trials":806,"activeCount":68},[],{"trials":808,"activeCount":68},[],{"trials":810,"activeCount":68},[811],{"nctId":788,"briefTitle":789,"status":88,"phases":812,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":813,"interventions":814},[59],[15],[777,796],{"trials":816,"activeCount":68},[],{"trials":818,"activeCount":68},[],{"intervention":820,"totalTrials":183,"cells":821},"Folinic Acid, interferon-alpha",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":840,"NA":842},{"trials":823,"activeCount":68},[],{"trials":825,"activeCount":68},[],{"trials":827,"activeCount":68},[],{"trials":829,"activeCount":68},[830],{"nctId":831,"briefTitle":832,"status":76,"phases":833,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":839},"NCT01060501","Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer",[59],"2009-07","1992-07",796,[838],"Rectal Cancer",[820],{"trials":841,"activeCount":68},[],{"trials":843,"activeCount":68},[],{"intervention":147,"totalTrials":183,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":858,"NA":860},{"trials":847,"activeCount":68},[],{"trials":849,"activeCount":68},[],{"trials":851,"activeCount":68},[],{"trials":853,"activeCount":68},[854],{"nctId":137,"briefTitle":138,"status":76,"phases":855,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":856,"interventions":857},[58,59],[15],[44,120,121,146,147],{"trials":859,"activeCount":68},[],{"trials":861,"activeCount":68},[],{"intervention":863,"totalTrials":183,"cells":864},"ferric carboxymaltose",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":885,"NA":887},{"trials":866,"activeCount":68},[],{"trials":868,"activeCount":68},[],{"trials":870,"activeCount":68},[],{"trials":872,"activeCount":68},[873],{"nctId":874,"briefTitle":875,"status":88,"phases":876,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":884},"NCT01837082","Iron in Congestive Heart Failure",[59],"2015-12","2013-04",18,[881,882,883],"Heart Failure","Iron Deficiency","Anemia",[863],{"trials":886,"activeCount":68},[],{"trials":888,"activeCount":68},[],{"intervention":890,"totalTrials":183,"cells":891},"Dexamethasone, Rituximab, Cyclophosphamide",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":912,"NA":914},{"trials":893,"activeCount":68},[],{"trials":895,"activeCount":68},[],{"trials":897,"activeCount":68},[],{"trials":899,"activeCount":68},[900],{"nctId":901,"briefTitle":902,"status":76,"phases":903,"primaryCompletion":904,"completion":905,"start":906,"enrollment":907,"conditions":908,"interventions":910},"NCT01788020","Efficacy of First Line DRC +\u002F- Bortezomib for Patients With Waldenström's Macroglobulinemia",[59],"2018-11","2024-04","2013-11",202,[909],"Waldenström's Macroglobulinemia",[890,911],"Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib",{"trials":913,"activeCount":68},[],{"trials":915,"activeCount":68},[],{"intervention":911,"totalTrials":183,"cells":917},{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":922,"PHASE3":924,"PHASE4":930,"NA":932},{"trials":919,"activeCount":68},[],{"trials":921,"activeCount":68},[],{"trials":923,"activeCount":68},[],{"trials":925,"activeCount":68},[926],{"nctId":901,"briefTitle":902,"status":76,"phases":927,"primaryCompletion":904,"completion":905,"start":906,"enrollment":907,"conditions":928,"interventions":929},[59],[909],[890,911],{"trials":931,"activeCount":68},[],{"trials":933,"activeCount":68},[],{"intervention":640,"totalTrials":183,"cells":935},{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":948,"NA":950},{"trials":937,"activeCount":68},[],{"trials":939,"activeCount":68},[],{"trials":941,"activeCount":68},[],{"trials":943,"activeCount":68},[944],{"nctId":632,"briefTitle":633,"status":76,"phases":945,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":946,"interventions":947},[59],[15],[120,640,121,641],{"trials":949,"activeCount":68},[],{"trials":951,"activeCount":68},[],{"intervention":641,"totalTrials":183,"cells":953},{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":966,"NA":968},{"trials":955,"activeCount":68},[],{"trials":957,"activeCount":68},[],{"trials":959,"activeCount":68},[],{"trials":961,"activeCount":68},[962],{"nctId":632,"briefTitle":633,"status":76,"phases":963,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":964,"interventions":965},[59],[15],[120,640,121,641],{"trials":967,"activeCount":68},[],{"trials":969,"activeCount":68},[],{"intervention":182,"totalTrials":183,"cells":971},{"EARLY_PHASE1":972,"PHASE1":974,"PHASE2":976,"PHASE3":978,"PHASE4":984,"NA":986},{"trials":973,"activeCount":68},[],{"trials":975,"activeCount":68},[],{"trials":977,"activeCount":68},[],{"trials":979,"activeCount":68},[980],{"nctId":175,"briefTitle":176,"status":76,"phases":981,"primaryCompletion":79,"completion":178,"start":103,"enrollment":179,"conditions":982,"interventions":983},[59],[15],[44,120,146,97,182],{"trials":985,"activeCount":68},[],{"trials":987,"activeCount":68},[],{"intervention":122,"totalTrials":225,"cells":989},{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":991,"activeCount":68},[],{"trials":993,"activeCount":68},[],{"trials":995,"activeCount":68},[996,1006],{"nctId":997,"briefTitle":998,"status":76,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":793,"conditions":1002,"interventions":1004},"NCT03338348","Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2",[58],"2019-10-31","2018-04-19",[15,1003],"Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)",[1005,122],"Vosaroxin",{"nctId":111,"briefTitle":112,"status":76,"phases":1007,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":1008,"interventions":1009},[58],[18],[44,120,121,122,123],{"trials":1011,"activeCount":68},[],{"trials":1013,"activeCount":68},[],{"trials":1015,"activeCount":68},[],{"intervention":1017,"totalTrials":183,"cells":1018},"Eltrombopag",{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1020,"activeCount":68},[],{"trials":1022,"activeCount":68},[],{"trials":1024,"activeCount":68},[1025],{"nctId":1026,"briefTitle":1027,"status":88,"phases":1028,"primaryCompletion":906,"completion":1029,"start":1030,"enrollment":26,"conditions":1031,"interventions":1034},"NCT01397149","Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)",[57,58],"2014-11","2011-10",[1032,1033],"Chronic Lymphocytic Leukemia","Thrombocytopenia",[1017],{"trials":1036,"activeCount":68},[],{"trials":1038,"activeCount":68},[],{"trials":1040,"activeCount":68},[],{"intervention":1042,"totalTrials":183,"cells":1043},"Cabazitaxel",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1045,"activeCount":68},[],{"trials":1047,"activeCount":68},[],{"trials":1049,"activeCount":68},[1050],{"nctId":1051,"briefTitle":1052,"status":76,"phases":1053,"primaryCompletion":428,"completion":1054,"start":1055,"enrollment":472,"conditions":1056,"interventions":1058},"NCT01866449","Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme",[58],"2017-08-25","2013-10",[1057],"Glioblastoma Multiforme (GBM) WHO Grade IV",[1042],{"trials":1060,"activeCount":68},[],{"trials":1062,"activeCount":68},[],{"trials":1064,"activeCount":68},[],{"intervention":1066,"totalTrials":183,"cells":1067},"sodium 2-mercaptoethane sulfonate",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1086,"PHASE4":1088,"NA":1090},{"trials":1069,"activeCount":68},[],{"trials":1071,"activeCount":68},[],{"trials":1073,"activeCount":68},[1074],{"nctId":1075,"briefTitle":1076,"status":76,"phases":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1085},"NCT00223548","MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application",[58],"2004-12","2002-10",106,[1082,1083,1084],"Chronic Renal Insufficiency","Serum Creatinine Concentration","Contrast Media Exposition",[1066],{"trials":1087,"activeCount":68},[],{"trials":1089,"activeCount":68},[],{"trials":1091,"activeCount":68},[],{"intervention":1093,"totalTrials":183,"cells":1094},"Aflibercept",{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1096,"activeCount":68},[],{"trials":1098,"activeCount":68},[],{"trials":1100,"activeCount":68},[1101],{"nctId":1102,"briefTitle":1103,"status":425,"phases":1104,"primaryCompletion":1105,"completion":1106,"start":1107,"enrollment":1108,"conditions":1109,"interventions":1111},"NCT02331927","PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer",[58],"2020-03","2021-03","2015-03",150,[1110],"Metastatic Colorectal Cancer",[1093],{"trials":1113,"activeCount":68},[],{"trials":1115,"activeCount":68},[],{"trials":1117,"activeCount":68},[],{"intervention":1005,"totalTrials":183,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1130,"PHASE4":1132,"NA":1134},{"trials":1121,"activeCount":68},[],{"trials":1123,"activeCount":68},[],{"trials":1125,"activeCount":68},[1126],{"nctId":997,"briefTitle":998,"status":76,"phases":1127,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":793,"conditions":1128,"interventions":1129},[58],[15,1003],[1005,122],{"trials":1131,"activeCount":68},[],{"trials":1133,"activeCount":68},[],{"trials":1135,"activeCount":68},[],{"intervention":95,"totalTrials":183,"cells":1137},{"EARLY_PHASE1":1138,"PHASE1":1140,"PHASE2":1142,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1139,"activeCount":68},[],{"trials":1141,"activeCount":68},[],{"trials":1143,"activeCount":68},[1144],{"nctId":86,"briefTitle":87,"status":88,"phases":1145,"primaryCompletion":90,"completion":90,"start":91,"enrollment":19,"conditions":1146,"interventions":1147},[58],[18,93],[95,44,96,97],{"trials":1149,"activeCount":68},[],{"trials":1151,"activeCount":68},[],{"trials":1153,"activeCount":68},[],{"intervention":1155,"totalTrials":183,"cells":1156},"Rasagiline",{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1173,"PHASE4":1175,"NA":1177},{"trials":1158,"activeCount":68},[],{"trials":1160,"activeCount":68},[],{"trials":1162,"activeCount":68},[1163],{"nctId":1164,"briefTitle":1165,"status":76,"phases":1166,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1172},"NCT01879241","Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis",[58],"2016-04","2016-08","2013-06",252,[21],[1155],{"trials":1174,"activeCount":68},[],{"trials":1176,"activeCount":68},[],{"trials":1178,"activeCount":68},[],{"intervention":1180,"totalTrials":183,"cells":1181},"Alemtuzumab",{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1183,"activeCount":68},[],{"trials":1185,"activeCount":68},[],{"trials":1187,"activeCount":68},[1188],{"nctId":1189,"briefTitle":1190,"status":76,"phases":1191,"primaryCompletion":1192,"completion":1193,"start":1194,"enrollment":1195,"conditions":1196,"interventions":1197},"NCT01392079","Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine",[58],"2012-01","2016-03","2008-02",135,[1032],[1180],{"trials":1199,"activeCount":68},[],{"trials":1201,"activeCount":68},[],{"trials":1203,"activeCount":68},[],{"intervention":1205,"totalTrials":183,"cells":1206},"pioglitazone",{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1208,"activeCount":68},[],{"trials":1210,"activeCount":68},[],{"trials":1212,"activeCount":68},[1213],{"nctId":1214,"briefTitle":1215,"status":88,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1220,"interventions":1221},"NCT00690118","Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis",[58],"2010-06","2008-05",219,[21],[1205],{"trials":1223,"activeCount":68},[],{"trials":1225,"activeCount":68},[],{"trials":1227,"activeCount":68},[],{"intervention":1229,"totalTrials":183,"cells":1230},"Rituximab",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1248,"PHASE4":1250,"NA":1252},{"trials":1232,"activeCount":68},[],{"trials":1234,"activeCount":68},[],{"trials":1236,"activeCount":68},[1237],{"nctId":1238,"briefTitle":1239,"status":88,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1244,"interventions":1246},"NCT04268277","Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY",[58],"2024-12-06","2022-03-01",22,[1245],"Marginal Zone Lymphoma",[1229,1247],"Pembrolizumab",{"trials":1249,"activeCount":68},[],{"trials":1251,"activeCount":68},[],{"trials":1253,"activeCount":68},[],{"intervention":1247,"totalTrials":183,"cells":1255},{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1266,"PHASE4":1268,"NA":1270},{"trials":1257,"activeCount":68},[],{"trials":1259,"activeCount":68},[],{"trials":1261,"activeCount":68},[1262],{"nctId":1238,"briefTitle":1239,"status":88,"phases":1263,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1264,"interventions":1265},[58],[1245],[1229,1247],{"trials":1267,"activeCount":68},[],{"trials":1269,"activeCount":68},[],{"trials":1271,"activeCount":68},[],{"intervention":1273,"totalTrials":183,"cells":1274},"Temozolomide",{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1299,"PHASE4":1301,"NA":1303},{"trials":1276,"activeCount":68},[],{"trials":1278,"activeCount":68},[],{"trials":1280,"activeCount":68},[1281],{"nctId":1282,"briefTitle":1283,"status":76,"phases":1284,"primaryCompletion":1285,"completion":1286,"start":90,"enrollment":64,"conditions":1287,"interventions":1289},"NCT02770378","A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma",[57,58],"2018-10","2020-12",[1288],"Glioblastoma",[1273,1290,1291,1292,1293,1294,1295,1296,1297,1298],"Aprepitant","Minocycline","Disulfiram","Celecoxib","Sertraline","Captopril","Itraconazole","Ritonavir","Auranofin",{"trials":1300,"activeCount":68},[],{"trials":1302,"activeCount":68},[],{"trials":1304,"activeCount":68},[],{"intervention":1290,"totalTrials":183,"cells":1306},{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1317,"PHASE4":1319,"NA":1321},{"trials":1308,"activeCount":68},[],{"trials":1310,"activeCount":68},[],{"trials":1312,"activeCount":68},[1313],{"nctId":1282,"briefTitle":1283,"status":76,"phases":1314,"primaryCompletion":1285,"completion":1286,"start":90,"enrollment":64,"conditions":1315,"interventions":1316},[57,58],[1288],[1273,1290,1291,1292,1293,1294,1295,1296,1297,1298],{"trials":1318,"activeCount":68},[],{"trials":1320,"activeCount":68},[],{"trials":1322,"activeCount":68},[],{"intervention":1291,"totalTrials":183,"cells":1324},{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1335,"PHASE4":1337,"NA":1339},{"trials":1326,"activeCount":68},[],{"trials":1328,"activeCount":68},[],{"trials":1330,"activeCount":68},[1331],{"nctId":1282,"briefTitle":1283,"status":76,"phases":1332,"primaryCompletion":1285,"completion":1286,"start":90,"enrollment":64,"conditions":1333,"interventions":1334},[57,58],[1288],[1273,1290,1291,1292,1293,1294,1295,1296,1297,1298],{"trials":1336,"activeCount":68},[],{"trials":1338,"activeCount":68},[],{"trials":1340,"activeCount":68},[],{"intervention":1292,"totalTrials":183,"cells":1342},{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1353,"PHASE4":1355,"NA":1357},{"trials":1344,"activeCount":68},[],{"trials":1346,"activeCount":68},[],{"trials":1348,"activeCount":68},[1349],{"nctId":1282,"briefTitle":1283,"status":76,"phases":1350,"primaryCompletion":1285,"completion":1286,"start":90,"enrollment":64,"conditions":1351,"interventions":1352},[57,58],[1288],[1273,1290,1291,1292,1293,1294,1295,1296,1297,1298],{"trials":1354,"activeCount":68},[],{"trials":1356,"activeCount":68},[],{"trials":1358,"activeCount":68},[],{"intervention":1293,"totalTrials":183,"cells":1360},{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1371,"PHASE4":1373,"NA":1375},{"trials":1362,"activeCount":68},[],{"trials":1364,"activeCount":68},[],{"trials":1366,"activeCount":68},[1367],{"nctId":1282,"briefTitle":1283,"status":76,"phases":1368,"primaryCompletion":1285,"completion":1286,"start":90,"enrollment":64,"conditions":1369,"interventions":1370},[57,58],[1288],[1273,1290,1291,1292,1293,1294,1295,1296,1297,1298],{"trials":1372,"activeCount":68},[],{"trials":1374,"activeCount":68},[],{"trials":1376,"activeCount":68},[],{"intervention":1294,"totalTrials":183,"cells":1378},{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1380,"activeCount":68},[],{"trials":1382,"activeCount":68},[],{"trials":1384,"activeCount":68},[1385],{"nctId":1282,"briefTitle":1283,"status":76,"phases":1386,"primaryCompletion":1285,"completion":1286,"start":90,"enrollment":64,"conditions":1387,"interventions":1388},[57,58],[1288],[1273,1290,1291,1292,1293,1294,1295,1296,1297,1298],{"trials":1390,"activeCount":68},[],{"trials":1392,"activeCount":68},[],{"trials":1394,"activeCount":68},[],{"intervention":1295,"totalTrials":183,"cells":1396},{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1401,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1398,"activeCount":68},[],{"trials":1400,"activeCount":68},[],{"trials":1402,"activeCount":68},[1403],{"nctId":1282,"briefTitle":1283,"status":76,"phases":1404,"primaryCompletion":1285,"completion":1286,"start":90,"enrollment":64,"conditions":1405,"interventions":1406},[57,58],[1288],[1273,1290,1291,1292,1293,1294,1295,1296,1297,1298],{"trials":1408,"activeCount":68},[],{"trials":1410,"activeCount":68},[],{"trials":1412,"activeCount":68},[],{"intervention":1296,"totalTrials":183,"cells":1414},{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1425,"PHASE4":1427,"NA":1429},{"trials":1416,"activeCount":68},[],{"trials":1418,"activeCount":68},[],{"trials":1420,"activeCount":68},[1421],{"nctId":1282,"briefTitle":1283,"status":76,"phases":1422,"primaryCompletion":1285,"completion":1286,"start":90,"enrollment":64,"conditions":1423,"interventions":1424},[57,58],[1288],[1273,1290,1291,1292,1293,1294,1295,1296,1297,1298],{"trials":1426,"activeCount":68},[],{"trials":1428,"activeCount":68},[],{"trials":1430,"activeCount":68},[],{"intervention":1297,"totalTrials":183,"cells":1432},{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1443,"PHASE4":1445,"NA":1447},{"trials":1434,"activeCount":68},[],{"trials":1436,"activeCount":68},[],{"trials":1438,"activeCount":68},[1439],{"nctId":1282,"briefTitle":1283,"status":76,"phases":1440,"primaryCompletion":1285,"completion":1286,"start":90,"enrollment":64,"conditions":1441,"interventions":1442},[57,58],[1288],[1273,1290,1291,1292,1293,1294,1295,1296,1297,1298],{"trials":1444,"activeCount":68},[],{"trials":1446,"activeCount":68},[],{"trials":1448,"activeCount":68},[],{"intervention":1298,"totalTrials":183,"cells":1450},{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1452,"activeCount":68},[],{"trials":1454,"activeCount":68},[],{"trials":1456,"activeCount":68},[1457],{"nctId":1282,"briefTitle":1283,"status":76,"phases":1458,"primaryCompletion":1285,"completion":1286,"start":90,"enrollment":64,"conditions":1459,"interventions":1460},[57,58],[1288],[1273,1290,1291,1292,1293,1294,1295,1296,1297,1298],{"trials":1462,"activeCount":68},[],{"trials":1464,"activeCount":68},[],{"trials":1466,"activeCount":68},[],{"intervention":1468,"totalTrials":183,"cells":1469},"Pomalidomide",{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1485,"PHASE4":1487,"NA":1489},{"trials":1471,"activeCount":68},[],{"trials":1473,"activeCount":68},[],{"trials":1475,"activeCount":68},[1476],{"nctId":1477,"briefTitle":1478,"status":76,"phases":1479,"primaryCompletion":1480,"completion":1480,"start":371,"enrollment":1481,"conditions":1482,"interventions":1484},"NCT00949364","Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage",[58],"2016-12-14",103,[1483],"Myeloproliferative Neoplasms",[1468],{"trials":1486,"activeCount":68},[],{"trials":1488,"activeCount":68},[],{"trials":1490,"activeCount":68},[],{"intervention":1492,"totalTrials":183,"cells":1493},"Palbociclib",{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1510,"PHASE4":1512,"NA":1514},{"trials":1495,"activeCount":68},[],{"trials":1497,"activeCount":68},[],{"trials":1499,"activeCount":68},[1500],{"nctId":1501,"briefTitle":1502,"status":425,"phases":1503,"primaryCompletion":1504,"completion":1504,"start":1505,"enrollment":1506,"conditions":1507,"interventions":1509},"NCT02310243","Study of Palbociclib in MLL-rearranged Acute Leukemias",[57,58],"2019-07","2015-07",50,[15,1508],"Acute Lymphoblastic Leukemia",[1492],{"trials":1511,"activeCount":68},[],{"trials":1513,"activeCount":68},[],{"trials":1515,"activeCount":68},[],{"intervention":1517,"totalTrials":183,"cells":1518},"FUFA",{"EARLY_PHASE1":1519,"PHASE1":1521,"PHASE2":1523,"PHASE3":1540,"PHASE4":1542,"NA":1544},{"trials":1520,"activeCount":68},[],{"trials":1522,"activeCount":68},[],{"trials":1524,"activeCount":68},[1525],{"nctId":1526,"briefTitle":1527,"status":76,"phases":1528,"primaryCompletion":1217,"completion":1529,"start":1530,"enrollment":1531,"conditions":1532,"interventions":1538},"NCT01212718","Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase",[58],"2010-09","2001-07",168,[1533,1534,1535,1536,1537],"Colorectal Cancer","Non Resectable Metastasis","Reference Lesion","Biopsy","Thymidylate Synthase Quantitation",[1517,1539],"systemic chemotherapy",{"trials":1541,"activeCount":68},[],{"trials":1543,"activeCount":68},[],{"trials":1545,"activeCount":68},[],{"intervention":1539,"totalTrials":183,"cells":1547},{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1558,"PHASE4":1560,"NA":1562},{"trials":1549,"activeCount":68},[],{"trials":1551,"activeCount":68},[],{"trials":1553,"activeCount":68},[1554],{"nctId":1526,"briefTitle":1527,"status":76,"phases":1555,"primaryCompletion":1217,"completion":1529,"start":1530,"enrollment":1531,"conditions":1556,"interventions":1557},[58],[1533,1534,1535,1536,1537],[1517,1539],{"trials":1559,"activeCount":68},[],{"trials":1561,"activeCount":68},[],{"trials":1563,"activeCount":68},[],{"intervention":1565,"totalTrials":183,"cells":1566},"INCB018424\u002FCC-4047",{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1587,"PHASE4":1589,"NA":1591},{"trials":1568,"activeCount":68},[],{"trials":1570,"activeCount":68},[],{"trials":1572,"activeCount":68},[1573],{"nctId":1574,"briefTitle":1575,"status":76,"phases":1576,"primaryCompletion":905,"completion":1577,"start":141,"enrollment":1578,"conditions":1579,"interventions":1586},"NCT01644110","Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF",[57,58],"2024-04-27",96,[1580,1581,1582,1583,1584,1585],"Primary Myelofibrosis","Secondary Myelofibrosis","PMF","SMF","Post-PV MF","Post-ET MF",[1565],{"trials":1588,"activeCount":68},[],{"trials":1590,"activeCount":68},[],{"trials":1592,"activeCount":68},[],{"intervention":277,"totalTrials":183,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1605,"PHASE4":1607,"NA":1609},{"trials":1596,"activeCount":68},[],{"trials":1598,"activeCount":68},[],{"trials":1600,"activeCount":68},[1601],{"nctId":267,"briefTitle":268,"status":76,"phases":1602,"primaryCompletion":270,"completion":271,"start":272,"enrollment":273,"conditions":1603,"interventions":1604},[58],[275],[277,278,258],{"trials":1606,"activeCount":68},[],{"trials":1608,"activeCount":68},[],{"trials":1610,"activeCount":68},[],{"intervention":278,"totalTrials":183,"cells":1612},{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1623,"PHASE4":1625,"NA":1627},{"trials":1614,"activeCount":68},[],{"trials":1616,"activeCount":68},[],{"trials":1618,"activeCount":68},[1619],{"nctId":267,"briefTitle":268,"status":76,"phases":1620,"primaryCompletion":270,"completion":271,"start":272,"enrollment":273,"conditions":1621,"interventions":1622},[58],[275],[277,278,258],{"trials":1624,"activeCount":68},[],{"trials":1626,"activeCount":68},[],{"trials":1628,"activeCount":68},[],{"intervention":1630,"totalTrials":183,"cells":1631},"Docetaxel",{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1633,"activeCount":68},[],{"trials":1635,"activeCount":68},[],{"trials":1637,"activeCount":68},[1638],{"nctId":1639,"briefTitle":1640,"status":425,"phases":1641,"primaryCompletion":1642,"completion":1642,"start":1643,"enrollment":1644,"conditions":1645,"interventions":1647},"NCT00690300","Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer",[58],"2010-12","2008-01",44,[1646],"Pancreas Neoplasms",[1630,1648],"Oxaliplatin",{"trials":1650,"activeCount":68},[],{"trials":1652,"activeCount":68},[],{"trials":1654,"activeCount":68},[],{"intervention":1648,"totalTrials":183,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1658,"activeCount":68},[],{"trials":1660,"activeCount":68},[],{"trials":1662,"activeCount":68},[1663],{"nctId":1639,"briefTitle":1640,"status":425,"phases":1664,"primaryCompletion":1642,"completion":1642,"start":1643,"enrollment":1644,"conditions":1665,"interventions":1666},[58],[1646],[1630,1648],{"trials":1668,"activeCount":68},[],{"trials":1670,"activeCount":68},[],{"trials":1672,"activeCount":68},[],{"intervention":109,"totalTrials":183,"cells":1674},{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1685,"PHASE4":1687,"NA":1689},{"trials":1676,"activeCount":68},[],{"trials":1678,"activeCount":68},[],{"trials":1680,"activeCount":68},[1681],{"nctId":99,"briefTitle":100,"status":76,"phases":1682,"primaryCompletion":102,"completion":79,"start":103,"enrollment":104,"conditions":1683,"interventions":1684},[58],[106],[44,97,108,109],{"trials":1686,"activeCount":68},[],{"trials":1688,"activeCount":68},[],{"trials":1690,"activeCount":68},[],{"intervention":123,"totalTrials":183,"cells":1692},{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1697,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1694,"activeCount":68},[],{"trials":1696,"activeCount":68},[],{"trials":1698,"activeCount":68},[1699],{"nctId":111,"briefTitle":112,"status":76,"phases":1700,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":1701,"interventions":1702},[58],[18],[44,120,121,122,123],{"trials":1704,"activeCount":68},[],{"trials":1706,"activeCount":68},[],{"trials":1708,"activeCount":68},[],{"intervention":133,"totalTrials":183,"cells":1710},{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1715,"PHASE3":1721,"PHASE4":1723,"NA":1725},{"trials":1712,"activeCount":68},[],{"trials":1714,"activeCount":68},[],{"trials":1716,"activeCount":68},[1717],{"nctId":125,"briefTitle":126,"status":76,"phases":1718,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":1719,"interventions":1720},[58],[15],[133,44,96],{"trials":1722,"activeCount":68},[],{"trials":1724,"activeCount":68},[],{"trials":1726,"activeCount":68},[],{"intervention":1728,"totalTrials":183,"cells":1729},"lenalidomide",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1743,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1731,"activeCount":68},[],{"trials":1733,"activeCount":68},[1734],{"nctId":1735,"briefTitle":1736,"status":88,"phases":1737,"primaryCompletion":1738,"completion":1738,"start":1739,"enrollment":1740,"conditions":1741,"interventions":1742},"NCT00839059","Lenalidomide In Patients With Acute Myeloid Leukemia",[57],"2011-05","2009-01",14,[15],[1728],{"trials":1744,"activeCount":68},[],{"trials":1746,"activeCount":68},[],{"trials":1748,"activeCount":68},[],{"trials":1750,"activeCount":68},[],{"intervention":1752,"totalTrials":225,"cells":1753},"Oral administration of ferrous sulphate",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1760,"PHASE4":1762,"NA":1764},{"trials":1755,"activeCount":68},[],{"trials":1757,"activeCount":68},[],{"trials":1759,"activeCount":68},[],{"trials":1761,"activeCount":68},[],{"trials":1763,"activeCount":68},[],{"trials":1765,"activeCount":68},[1766,1776],{"nctId":1767,"briefTitle":1768,"status":76,"phases":1769,"completion":1770,"start":1771,"enrollment":162,"conditions":1772,"interventions":1775},"NCT00457990","Neurodevelopment After Early Iron Supplementation",[61],"2005-12","2002-04",[882,1773,1774],"Anemia of Prematurity","Neurodevelopmental Delay",[1752],{"nctId":1777,"briefTitle":1778,"status":76,"phases":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":1783,"interventions":1784},"NCT00458068","Early Versus Late Enteral Iron in Infants Less Than 1301 Grams",[61],"1999-09","1996-06",126,[882,1773],[1752],{"intervention":1786,"totalTrials":183,"cells":1787},"Polypectomy and NGS",{"EARLY_PHASE1":1788,"PHASE1":1790,"PHASE2":1792,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1789,"activeCount":68},[],{"trials":1791,"activeCount":68},[],{"trials":1793,"activeCount":68},[],{"trials":1795,"activeCount":68},[],{"trials":1797,"activeCount":68},[],{"trials":1799,"activeCount":68},[1800],{"nctId":1801,"briefTitle":1802,"status":76,"phases":1803,"primaryCompletion":1168,"completion":1804,"start":1805,"enrollment":1806,"conditions":1807,"interventions":1809},"NCT02595645","GENESIS: Genetic Biopsy for Prediction of Surveillance Intervals After Endoscopic Resection of Colonic Polyps",[61],"2016-10","2015-08",101,[1808],"Colonic Polyps",[1786],{"intervention":1811,"totalTrials":183,"cells":1812},"Triamcinolone",{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1819,"PHASE4":1821,"NA":1823},{"trials":1814,"activeCount":68},[],{"trials":1816,"activeCount":68},[],{"trials":1818,"activeCount":68},[],{"trials":1820,"activeCount":68},[],{"trials":1822,"activeCount":68},[],{"trials":1824,"activeCount":68},[1825],{"nctId":1826,"briefTitle":1827,"status":76,"phases":1828,"primaryCompletion":1804,"completion":1804,"start":161,"enrollment":879,"conditions":1829,"interventions":1831},"NCT02962518","Pressure Device in the Treatment of Ear Keloids",[61],[1830],"Keloid Ear",[1811],{"intervention":1833,"totalTrials":183,"cells":1834},"treated without",{"EARLY_PHASE1":1835,"PHASE1":1837,"PHASE2":1839,"PHASE3":1841,"PHASE4":1843,"NA":1845},{"trials":1836,"activeCount":68},[],{"trials":1838,"activeCount":68},[],{"trials":1840,"activeCount":68},[],{"trials":1842,"activeCount":68},[],{"trials":1844,"activeCount":68},[],{"trials":1846,"activeCount":68},[1847],{"nctId":1848,"briefTitle":1849,"status":76,"phases":1850,"primaryCompletion":1851,"completion":1852,"start":1853,"enrollment":104,"conditions":1854,"interventions":1858},"NCT06233357","Critically Ill ICU Patients Under Casirivimab- and\u002For Tocilizumab Application",[],"2022-04-28","2023-12-31","2021-08-01",[349,1855,1856,1857,28],"Outcome, Fatal","Tocilizumab","Interleukin 6",[1833],{"intervention":1860,"totalTrials":183,"cells":1861},"Oxygen",{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1866,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1863,"activeCount":68},[],{"trials":1865,"activeCount":68},[],{"trials":1867,"activeCount":68},[],{"trials":1869,"activeCount":68},[],{"trials":1871,"activeCount":68},[],{"trials":1873,"activeCount":68},[1874],{"nctId":1875,"briefTitle":1876,"status":425,"phases":1877,"primaryCompletion":1878,"completion":1879,"start":1880,"enrollment":1881,"conditions":1882,"interventions":1885},"NCT02743988","Influence of Oxygen Target Range on Intermittent Hypoxemia in Preterm Infants",[61],"2017-04","2017-09","2015-05",36,[1883,1884],"Intermittent Hypoxemia","Apnea of Prematurity",[1860],{"intervention":1887,"totalTrials":183,"cells":1888},"atorvastatin",{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1890,"activeCount":68},[],{"trials":1892,"activeCount":68},[],{"trials":1894,"activeCount":68},[],{"trials":1896,"activeCount":68},[],{"trials":1898,"activeCount":68},[],{"trials":1900,"activeCount":68},[1901],{"nctId":1902,"briefTitle":1903,"status":76,"phases":1904,"completion":1905,"start":1906,"enrollment":1506,"conditions":1907,"interventions":1910},"NCT00329069","The Role of Atorvastatin on Monocyte Function in Patients With Coronary Artery Disease and Hypercholesterolemia",[61],"2006-03","2002-05",[23,1908,1909],"Hypercholesterolemia","Monocyte Function",[1887],{"intervention":1912,"totalTrials":183,"cells":1913},"Indomethacin",{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1920,"PHASE4":1922,"NA":1924},{"trials":1915,"activeCount":68},[],{"trials":1917,"activeCount":68},[],{"trials":1919,"activeCount":68},[],{"trials":1921,"activeCount":68},[],{"trials":1923,"activeCount":68},[],{"trials":1925,"activeCount":68},[1926],{"nctId":1927,"briefTitle":1928,"status":76,"phases":1929,"primaryCompletion":1930,"completion":1193,"start":1931,"enrollment":1932,"conditions":1933,"interventions":1936},"NCT01428180","Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants",[],"2012-10","2011-04",35,[1934,1935],"Prematurity of Fetus","Patent Ductus Arteriosus",[1912,1937],"Ibuprofen",{"intervention":1937,"totalTrials":183,"cells":1939},{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1944,"PHASE3":1946,"PHASE4":1948,"NA":1950},{"trials":1941,"activeCount":68},[],{"trials":1943,"activeCount":68},[],{"trials":1945,"activeCount":68},[],{"trials":1947,"activeCount":68},[],{"trials":1949,"activeCount":68},[],{"trials":1951,"activeCount":68},[1952],{"nctId":1927,"briefTitle":1928,"status":76,"phases":1953,"primaryCompletion":1930,"completion":1193,"start":1931,"enrollment":1932,"conditions":1954,"interventions":1955},[],[1934,1935],[1912,1937],{"intervention":1957,"totalTrials":183,"cells":1958},"COVID-19 vaccines",{"EARLY_PHASE1":1959,"PHASE1":1961,"PHASE2":1963,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1960,"activeCount":68},[],{"trials":1962,"activeCount":68},[],{"trials":1964,"activeCount":68},[],{"trials":1966,"activeCount":68},[],{"trials":1968,"activeCount":68},[],{"trials":1970,"activeCount":68},[1971],{"nctId":1972,"briefTitle":1973,"status":425,"phases":1974,"primaryCompletion":1975,"completion":1976,"start":1977,"enrollment":179,"conditions":1978,"interventions":1980},"NCT04686409","App-based Symptom Tracking After Corona Vaccination (CoCoV)",[],"2022-01-31","2022-08-31","2021-01-11",[1979],"Adverse Events in COVID-19 Vaccination",[1957]]